



# ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260523017

Date: May 23, 2026

To, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India.  <b>SCRIP CODE: 543275</b>	To, <b>National Stock Exchange of India Limited</b> 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India.  <b>SYMBOL: ANURAS</b>
--	---

Dear Sir/Madam,

**Subject: Investor Presentation - Acquisition**

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the 'Investor Presentation' regarding Bliss GVS Pharma Limited Acquisition.

The Investor Presentation will also be hosted on the website of the Company at [www.anupamrasayan.com](http://www.anupamrasayan.com).

We kindly request you to note the same and take into your records.

Thanking you,

Yours Faithfully,

**For Anupam Rasayan India Limited**

**Ashish Gupta**  
**Company Secretary & Compliance Officer**

Encl: As above




ANUPAM RASAYAN INDIA LTD.

# Anupam Rasayan India Limited

Bliss GVS Pharma  
Acquisition

May 2026



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Anupam Rasayan India Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe to any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over-runs on contracts, our ability to manage our international operations, government policies and actions, regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

- Incorporated in 1984.
- Manufactures branded formulations across Anti-malarial, Anti-fungal, Anti-bacterial, Antibiotic, anti-inflammatory, Anti-infective, Anti-diabetic, Cardiovascular, Gastrointestinal, Respiratory, Urology and contraceptive segments.
- Renowned for its flagship anti-malarial WHO endorsed brand (Lonart).
- Long-standing distributor relationships (spanning over 20-25 years).
- Bliss GVS Pharma is the first EU-GMP certified suppositories manufacturer in India.
- 6 Manufacturing facilities in Palghar, Vevoor and Ambernath across Maharashtra.



**150+**  
Brands



**50+**  
Therapeutic  
segments



**16+**  
Dosage forms



**1,000+**  
Employees



**80+**  
Scientists

## Global Accreditations




& **25+** Accreditations




Signed Strategic agreements in USA and Canada and received US FDA approval for Palghar suppository unit which is expected to significantly contribute to revenue growth.

# Performance Trend : Bliss GVS Pharma


### Revenue (Rs. Crore)



### EBITDA (Rs. crore)



### PAT (Rs. crore)



**Rs 167 Crores**  
Cash & Cash Equivalents

**Zero**  
Net Debt

**Rs. 139 Crores**  
Cash Flow from Operations



### **Synergies with Therapeutic Areas:**

Expansion into Cardiovascular, Antidiabetic, Antibiotics, Analgesic & Anti-inflammatory, Anti-Retrovirals, Antifungals, Anti-depressant and Anti-malarial segments



### **Expansion into CDMO Business:**

Expanding into regulated markets through Vevoor facility.



### **Forward Integration:**

End-to-End Vertically integrated Manufacturing to give cost and resource leverage.



### **Capacity Utilization Ramp Up:**

Significant headroom available to improve capacity utilization (current capacity utilization is only 30%), supported by customer engagements, and increasing demand across key business segments



### **Expanding USA Footprint:**

Leveraging expertise of Anupam in North America and European markets to expand in regulated markets

## Key Therapeutic Areas

Cardiovascular

Anti-Diabetic

Antibiotics / Anti Bacterial

Analgesic, Anti-Inflammatory

Antiretrovirals


Antifungals

Anti-Depressant

Anti-Malarial

***Robust pipeline of 62+ molecules, with 48+ molecules catering to regulated markets, strengthening the Company's presence in high-entry-barrier segments***

# State-of-the-Art Manufacturing Facilities



## Palghar



### Dosage

- ✓ Tablet
- ✓ Dry syrup
- ✓ Sachet
- ✓ Suppository

**Capacity - 758 mn units**

## Vevoor



### Dosage

- ✓ Tablet
- ✓ Capsule
- ✓ Sachet
- ✓ Ointment
- ✓ Cream and Gel

**Capacity - 3,974 mn units**

## Ambernath



### Dosage

- ✓ Ointment
- ✓ Cream
- ✓ Gel

**Capacity - 90 mn units**

## Executed Capex Projects

- Vevoor Plant Capex: Rs. 260 crore
- Palghar Suppositories Plant Capex: Rs. 50 crore
- Vevoor Ointment Facility Plant Capex: Rs. 40 crore Awaiting Plant approval

## Ongoing Capex


- Halol Facility
- Capex of Rs. 250 crore


## Post Capex Execution

- Entry into regulated market
- Diversified Dosage Capabilities
- Enhanced Manufacturing footprint




## Deal overview

 **43.3-48.2%+ Open Offer to the public shareholders for controlling stake of Bliss GVS Pharma**, an India-based pharmaceutical formulations company engaged in the development, manufacturing, marketing, and export of a wide range of dosage forms

 **Source of Funds**  
(Term Loan of ~Rs 300 Crores & Non-Controlling Non-voting equity instrument for balance amount)

## Transaction structure





**Company Details:**



**ANUPAM RASAYAN INDIA LTD.**

**Anupam Rasayan Ltd.**

CIN – L24231GJ2003PLC042988

**Investor Relations Advisor :**

**SGA** Strategic Growth Advisors

**Strategic Growth Advisors Pvt. Ltd.**

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani / Ms. Shaily Patwa

Email - [shrikant.sangani@sgapl.net](mailto:shrikant.sangani@sgapl.net) / [shaily.p@sgapl.net](mailto:shaily.p@sgapl.net)

Mobile No – 9619595686 / 9819494608

[www.sgapl.net](http://www.sgapl.net)

**Thank You**